
==== Front
J Hematol
J Hematol
Elmer Press
Journal of Hematology
1927-1212
1927-1220
Elmer Press

10.14740/jh1259
Case Report
Breast Cancer With Release of Tumor Cells in Peripheral Blood Mimicking Acute Myeloid Leukemia
BC With Peripheral Tumor Cells Mimicking AML
Gatti Arianna aghttps://orcid.org/0000-0002-8611-0459

Brando Bruno a
Cuppari Irene a
Viola Nadia b
Brunetti Lorenzo c
Sampaolo Michela d
More Sonia c
Morichetti Doriana e
Corvatta Laura f
a Hematology Laboratory and Transfusion Center ASST Ovest Milanese-Ospedale Legnano, Milan, Italy
b Clinical Immunology Unit, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
c Department of Hematology, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
d Laboratory Medicine Unit, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
e Anatomical and Histopathological Pathology Unit, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
f Department of Medicine, Profili Hospital, Fabriano, Italy
g Corresponding Author: Arianna Gatti, Hematology Laboratory and Transfusion Center ASST Ovest Milanese-Ospedale Legnano, Milan, Italy. Email: arianna.gatti@asst-ovestmi.it
8 2024
18 7 2024
13 4 168173
26 3 2024
19 6 2024
Copyright 2024, Gatti et al.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
A 75-year-old woman with a history of lobular breast adenocarcinoma treated with mastectomy and radiotherapy in 2021 and on maintenance hormone therapy, presented with asthenia and tremors. Laboratory tests showed leucocytosis, anemia and low platelet count, with increased serum calcium, lactate dehydrogenase and indirect bilirubin levels. Haptoglobin was decreased and renal function was normal. Peripheral blood smear showed red cell anisocytosis, many schistocytes and immature granulocytes. Furthermore, 15% of white cells displayed large size and atypical morphology. A macroangiopathic hemolytic anemia (MAHA) related to a de novo or recurring cancer was hypothesized, and total body computed tomography (CT) and 18F-FDG positron emission tomography (PET)/CT were undertaken. Only a slight FDG uptake was demonstrated in the spine, attributable to a reactive bone marrow due to MAHA. Then, to rule out a MAHA related to acute leukemia, a bone marrow aspirate and trephine biopsy were performed, with an extensive cell immunophenotyping. The first myeloid flow cytometry (FC) panel evidenced a large volume population of about 20%, expressing CD117 but negative for CD45 and CD34. All myeloid markers were negative. A more extensive panel was then used, including plasma cell and erythroid markers. Interestingly, the abnormal population resulted positive for CD138 and CD71 with negativity for CD38. A recent study reported that besides CD45 negativity, non-hematological neoplasms frequently express CD56, CD117, or CD138. Therefore, a panel for non-hematological markers including epithelial cell adhesion molecule (EpCAM) was carried out. This population resulted EpCAM positive and also expressed CD9, a breast cancer prognostic marker. Bone marrow smears revealed the presence of the same cells, and the immunohistochemistry analysis of bone marrow biopsy demonstrated the massive infiltration of breast cancer cells, expressing all epithelial markers identified at diagnosis. The FC analysis of the peripheral blood allowed the rapid characterization of a non-hematological neoplastic cell population, circulating at unusually high frequency and mimicking an acute myeloid leukemia. The FC detection of CD45-negative cell populations in peripheral blood, bone marrow or lymph node aspirate should prompt the setup of an immunophenotyping panel including EpCAM, CD9, CD56 and CD117, to allow for a rapid and accurate identification of ectopic malignant epithelial cells.

Breast cancer
Macroangiopathic hemolytic anemia
Immunophenotyping
Flow cytometry
EpCAM
There is no external funding for this article.
==== Body
pmcIntroduction

Breast cancer (BC) is the most common malignancy among women in developed countries, with a mortality rate of 15%. Several studies have reported an increased incidence of acute myeloid leukemia (AML) after treatment of BC, with evidence of a dose-intensity relationship. Alkylating agents, topoisomerase II inhibitors and radiation therapy, fundamental to the treatment of BC, are the most likely contributors to increased risk of secondary AML [1, 2]. Another condition associated to BC is cancer-related microangiopathic hemolytic anemia (CR-MAHA) [3]. CR-MAHA is a paraneoplastic syndrome characterized by renal failure and/or neurological symptoms, increased schistocytes in the peripheral blood smear, negative direct antiglobulin test (DAT), hemolytic anemia with increased lactate dehydrogenase (LDH) level, increased indirect bilirubin, low haptoglobin and thrombocytopenia (< 150 × 109/L).

CR-MAHA is mostly associated with gastric cancer, followed by BC, prostate cancer, and lung cancer [4]. In literature, 51 cases of MAHA associated with BC are reported, most of them with poor outcome [5].

Here we describe the case of a patient with previous BC and a suspected CR-MAHA, however characterized by the detection of cells of unclear origin in the peripheral blood, at least initially suggesting a secondary AML.

Case Report

Investigations

A 75-year-old woman with a history of lobular breast adenocarcinoma (estrogen receptor (ER)-positive, progesterone receptor (PgR)-positive, human epidermal growth factor receptor 2 (HER2)-negative) treated with mastectomy and radiotherapy in 2021 and receiving hormone therapy, presented with asthenia and tremors. The full blood count showed leukocytosis (23.4 × 109/L with 56% neutrophils), anemia (Hb 72 g/L), macrocytosis (MCV 103 fL), slightly reduced platelet count (138 × 109/L) and increased reticulocytes (11%). Laboratory tests showed increased calcium level (13 mg/dL), LDH 600 U/L and indirect bilirubin (5 mg/dL), with undetectable haptoglobin (< 0.1 g/L). Tumor markers were negative. No coagulation abnormalities were documented. No changes of fibrinogen level were present, and no fibrinogen degradation product (FDP) was detected. ADAMTS13 testing was not carried out. DAT test was negative and renal function was normal. Peripheral blood smear showed marked red cell anisocytosis, a remarkable proportion of schistocytes (15% of erythrocytes), increased erythroblasts (3% of nucleated cells) and immature granulocytes (promyelocytes, myelocytes and metamyelocytes (Fig. 1a)). Furthermore, a significant number of large mononuclear cells of unclear lineage (15% of nucleated cells) were also detected (Fig. 1b).

Figure 1 Peripheral blood smear. (a) Marked red cell anisocytosis with a remarkable proportion of schistocytes (15% of erythrocytes, blue arrowheads) and erythroblasts (3% of nucleated cells, red arrowheads) was observed. (b) A significant number of large atypical mononuclear cells with eccentric nucleus, of uncertain lineage, were also noted (15% of nucleated cells).

Diagnosis

Therefore, in the hypothesis of a MAHA related to a de novo or relapsing cancer, total body CT scan and 18F-FDG PET/CT were ordered. The CT scan was negative, whereas only a slight 18F-FDG uptake was present in the spine, attributable to increased bone marrow activity due to MAHA. Subsequently, due to the presence of circulating abnormal cells and to exclude an acute leukemia-related MAHA, an immunophenotyping of peripheral blood cells, a bone marrow aspirate and a trephine biopsy were undertaken.

A first-level myeloid flow cytometry (FC) panel was initially performed. This panel evidenced a large sized CD45-negative cell population of about 20%, negative for CD34 and positive for CD117 (Fig. 2a). Myeloid markers, such as CD13, CD33 and CD11b were negative. Due to positivity for CD117 without expression of CD45, a more extensive panel was performed, including plasma cell markers (CD38, CD138, CD19, cytoplasmic immunoglobulin kappa and lambda light chains) and the erythroid marker CD71. Interestingly, this population resulted positive for CD138 and CD71, with negativity for CD38 (Fig. 2b). The plasma cell origin of this atypical population was excluded, therefore a second-level panel for non-hematological markers including the surface CD326 epithelial cell adhesion molecule (EpCAM) was carried out. This population resulted EpCAM positive, and also intensely expressed CD9 (Fig. 2c). Aspirate smears revealed the presence of the same cells and immunohistochemistry analysis of the bone marrow biopsy disclosed a massive infiltration of cells expressing all BC epithelial markers identified at diagnosis, such as cytokeratin, ER and GATA-binding protein 3 (GATA3) (Fig. 3). Because the immunohistochemistry results confirmed the infiltration by BC cells, G-band analysis of bone marrow and fluorescence in situ hybridization (FISH) testing were not performed.

Figure 2 Immunophenotypic analysis of peripheral blood. Green: lymphocytes; yellow: monocytes; pink: neutrophils; red: circulating breast cancer cells. (a) The first myeloid flow cytometry panel showed an atypical population (red) of 20%, negative for CD45 and CD34, positive for CD117 with high forward and side scatter. (b) A more extensive panel included plasma cell (CD138, CD38, CD19) and erythroid markers (CD71). The atypical population resulted positive for CD138 and CD71 with negativity for CD38. (c) A panel for non-hematological markers including CD326 epithelial cell adhesion molecule (EpCAM) was carried out. The abnormal population expressed EpCAM and CD9. The black rectangles indicate the areas of positive expression of cell markers, where applicable. FSC: forward scatter; SSC: side scatter; par: partial expression.

Figure 3 Immunohistochemistry analysis of bone marrow biopsy. A massive infiltration of cancer cells expressing all epithelial markers identified at diagnosis, such as cytokeratin (a), GATA-binding protein 3 (GATA3) (b) and estrogen receptor (c) was demonstrated.

Follow-up and outcomes

After a few days, the patient presented with high fever and 24 h later died for suspected septic shock. However, no microbiological data are available. No specific chemotherapy was undertaken. In absence of renal failure and/or neurological symptoms, no plasma-exchange was undertaken.

Discussion

Here we describe an unusual case of a patient with previous BC, who developed a clinical picture resembling CR-MAHA, due to an increased number of schistocytes, increased value of LDH and indirect bilirubin, low haptoglobin and mild thrombocytopenia, however without renal failure and/or neurological symptoms or coagulation abnormalities. The level of anemia remained stable during the hospitalization. These clinical features may be also associated to sepsis [6, 7], and the patient died shortly after being evaluated, with a clinical picture of likely septic shock. In any case, the diagnosis of CR-MAHA was excluded.

The most impressive feature of this case was the massive circulation of abnormal cells (15-20% of white cells) resembling an acute leukemia, that were demonstrated by FC to be of epithelial origin.

Rare tumor cells can be sometimes detected in the peripheral blood and bone marrow of patients with epithelial cancers, usually at very low concentration [8]. Many studies have shown that the number of circulating tumor cells (CTCs), as detected by a spectrum of techniques, can be correlated with disease progression and poor prognosis in various carcinomas [9-13]. It was reported that in about 58% of patients with BC, CTCs could be detected in peripheral blood, using immunomagnetic enrichment method based on fluorescent immunocytochemistry, with a sensitivity of one tumor cell in 1 × 107 peripheral blood mononuclear cells [14]. In another study, the CTCs were found in 71.4% of metastatic BC patients and the highest number of CTCs detected was 1,491 per 7.5 mL blood [15]. The direct detection of evident amounts of malignant tumor cells in peripheral blood by conventional FC is however reported in very few real-life studies [16, 17], with a maximum percentage of abnormal circulating cells between 5% and 9% of leukocytes.

In the present case, the FC analysis allowed the characterization of the non-hematological nature of an abnormal cell population, circulating at unusually high level in the peripheral blood (about 15-20% of white cells), mimicking AML. The resulting phenotyping of this population was CD45- CD34- CD13- CD33- CD38- CD9+ CD71+ CD117+ CD138+ CD326+. The initial AML hypothesis was supported by the positivity for CD117 and CD71. These markers are typically expressed in erythroid leukemia, in absence of CD45 and CD34 (FAB: M6), nevertheless the co-expression of CD138 and CD326 in erythroid leukemia has never been reported.

It is known that CD117 is expressed on KIT-dependent cell types, including mast cells, some hematopoietic stem cells, germ cells, melanocytes and erythroid precursors [18]. CD117-KIT is also expressed in pulmonary and other small cell carcinomas, adenoid cystic carcinoma, renal chromophobe carcinoma, thymoma, some ovarian cancers and in about 29% of BCs [19]. The lack of CD117 expression in invasive BC was reported to be associated with features of more aggressive tumor behavior with lymph node metastasis and negativity of ER and PgR [20]. Conversely, in the present report, a case of invasive CD117 positive BC is described. Furthermore, CD117 can be detected among 30% of malignant plasma cells, as identified by the CD138 lineage marker [21]. In our case, circulating BC cells co-expressed both markers. As reported by several studies, the expression of CD138 is also typically observed on the surface of mature epithelial cells (squamous and transition types) and in a variety of soft tissue tumors [22, 23]. In BC, the CD138 expression is controversial. Some studies reported cases of strong expression of CD138 on cancer cells in metastatic lobular carcinoma associated to poor prognosis [24, 25]. Other authors reported the shift from membranous and stromal CD138 expression to cytoplasmic CD138 expression as associated with poor prognosis in BC [26].

In this case report, FC allowed to quickly identify the epithelial nature of the abnormal circulating cells by the use of CD326 (EpCAM) marker. EpCAM is a transmembrane cell surface glycoprotein that is highly expressed in epithelial cancers and at lower levels in normal epithelia. Due to its frequent overexpression in carcinomas, EpCAM has been used as a diagnostic marker [27]. Several studies reported the usefulness of this marker for the detection of cancer cells by FC in various biological samples [28, 29]. Some groups have previously proposed different panels to identify non-hematopoietic neoplasms, including EpCAM in association with other markers such as CD45, CD56, CD71 or CD99 [30, 31]. In this study, we used a panel including CD326, CD138, CD45, CD117, CD71 and CD9. As reported by other authors, CD9 is widely expressed in various normal and cancer tissues [32, 33]. Non-neoplastic mammary epithelial cells were observed to be negative or weakly positive for CD9 expression, while the stromal inflammatory cells exhibited moderate-to-strong immunoreactivity for CD9 [34]. Baek and colleagues demonstrated that CD9 expression in patients with invasive lobular breast carcinoma is associated with poor prognosis [35]. Other authors reported an association between the overexpression of CD9 in human BC cells and the development of bone metastases [36]. Here we have described a case of metastatic BC, with peripheral blood and bone marrow invasion, strongly expressing CD9 and CD326, as evaluated by FC.

In conclusion, although FC is widely used in the diagnosis of hematological neoplasms and it is not routinely used in the diagnosis or follow-up of non-hematopoietic neoplasms, we demonstrated its usefulness, in a rare case with high-grade invasion of peripheral blood. The major limiting factor of this approach resides in the need of highlighting clusters of large sized CD45-negative cells, that may be overlooked in ordinary immunophenotypic analyses of peripheral blood, bone marrow or lymph node aspirates, when admixed with cell debris. It is reasonable to think that CD45-negative epithelial cell contaminants may become self-evident during routine FC analyses of hematopoietic cell suspensions only when greater than 4-5%.

FC may play the role of a useful ancillary test to conventional cytology and immunohistochemistry during the analysis of peripheral blood, bone marrow and lymph node aspirates showing unexpected clusters of CD45-negative cells.

None to declare.

Conflict of Interest

The authors declare no potential conflict of interest.

Informed Consent

According to our Ethical Committee, informed consent is not requested in retrospective clinical case studies after the death of the patient.

Author Contributions

AG and BB prepared the manuscript; IC, NV, LB, MS, SM, DM and LC managed the clinical case, collected the data and reviewed the manuscript.

Data Availability

The data supporting the findings of this study are available from the corresponding author upon reasonable request.
==== Refs
References

1 Valentini CG Fianchi L Voso MT Caira M Leone G Pagano L Incidence of acute myeloid leukemia after breast cancer Mediterr J Hematol Infect Dis 2011 3 1 e2011069 10.4084/MJHID.2011.069 22220266
2 Martin MG Welch JS Luo J Ellis MJ Graubert TA Walter MJ Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study Breast Cancer Res Treat 2009 118 3 593 598 10.1007/s10549-009-0376-3 19322652
3 Lechner K Obermeier HL Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases Medicine (Baltimore) 2012 91 4 195 205 10.1097/MD.0b013e3182603598 22732949
4 Thomas MR Scully M How I treat microangiopathic hemolytic anemia in patients with cancer Blood 2021 137 10 1310 1317 10.1182/blood.2019003810 33512445
5 Takabatake D Oishi K Microangiopathic hemolytic anemia associated with metastatic breast cancer: case report and literature review Springerplus 2016 5 1 684 10.1186/s40064-016-2312-4 27350919
6 Zini G d'Onofrio G Briggs C Erber W Jou JM Lee SH McFadden S et al ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes Int J Lab Hematol 2012 34 2 107 116 10.1111/j.1751-553X.2011.01380.x 22081912
7 Patel JJ Taneja A Niccum D Kumar G Jacobs E Nanchal R The association of serum bilirubin levels on the outcomes of severe sepsis J Intensive Care Med 2015 30 1 23 29 10.1177/0885066613488739 23753252
8 Lin D Shen L Luo M Zhang K Li J Yang Q Zhu F et al Circulating tumor cells: biology and clinical significance Signal Transduct Target Ther 2021 6 1 404 10.1038/s41392-021-00817-8 34803167
9 Cristofanilli M Budd GT Ellis MJ Stopeck A Matera J Miller MC Reuben JM et al Circulating tumor cells, disease progression, and survival in metastatic breast cancer N Engl J Med 2004 351 8 781 791 10.1056/NEJMoa040766 15317891
10 Potdar PD Lotey NK Role of circulating tumor cells in future diagnosis and therapy of cancer J Cancer Metastasis Treat 2015 1 44 56
11 Tieng FYF Abu N Nasir SN Lee LH Ab Mutalib NS Liquid biopsy-based colorectal cancer screening via surface markers of circulating tumor cells Diagnostics (Basel) 2021 11 11 2136 10.3390/diagnostics11112136 34829483
12 Garrido Castillo LN Mejean A Vielh P Anract J Decina A Nalpas B Benali-Furet N et al Predictive Value of Circulating Tumor Cells Detected by ISET((R)) in Patients with Non-Metastatic Prostate Cancer Undergoing Radical Prostatectomy Life (Basel) 2022 12 2 165 10.3390/life12020165 35207452
13 Gruijs M Zeelen C Hellingman T Smit J Borm FJ Kazemier G Dickhoff C et al Detection of Circulating Tumor Cells Using the Attune NxT Int J Mol Sci 2022 24 1 165 179 10.3390/ijms24010021 36613609
14 Cai QQ Huang HQ Lin TX Jiang WQ [Detection and clinical significance of circulating tumor cells in peripheral blood of breast cancer patients] Ai Zheng 2005 24 7 837 841 16004811
15 Riethdorf S Fritsche H Muller V Rau T Schindlbeck C Rack B Janni W et al Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system Clin Cancer Res 2007 13 3 920 928 10.1158/1078-0432.CCR-06-1695 17289886
16 Rowan DJ Logunova V van Tuinen P Olteanu H Peterson JF Circulating breast carcinoma cells mimicking therapy-related acute myeloid leukemia Int J Surg Pathol 2017 25 1 87 93 10.1177/1066896916664986 27543510
17 De Miguel Sanchez C Robles de Castro D Cordoba Alonso AI Guinea de Castro JM Diffuse bone marrow metastases of small cell carcinoma with associated erythrophagocytosis mimicking acute leukaemia Hematol Transfus Cell Ther 2022 44 3 459 461 10.1016/j.htct.2021.05.004 34266809
18 Miettinen M Lasota J KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation Appl Immunohistochem Mol Morphol 2005 13 3 205 220 10.1097/01.pai.0000173054.83414.22 16082245
19 Pan CC Chen PC Chiang H KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas J Pathol 2004 202 3 375 381 10.1002/path.1514 14991904
20 Amin MM El-Hawary AK Farouk O Relation of CD117 immunoreactivity and microvascular density in invasive breast carcinoma Indian J Pathol Microbiol 2012 55 4 456 460 10.4103/0377-4929.107780 23455779
21 Chen F Hu Y Wang X Fu S Liu Z Zhang J Expression of CD81 and CD117 in plasma cell myeloma and the relationship to prognosis Cancer Med 2018 7 12 5920 5927 10.1002/cam4.1840 30358164
22 O'Connell FP Pinkus JL Pinkus GS CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms Am J Clin Pathol 2004 121 2 254 263 10.1309/617D-WB5G-NFWX-HW4L 14983940
23 Orosz Z Kopper L Syndecan-1 expression in different soft tissue tumours Anticancer Res 2001 21 1B 733 737 11299835
24 Nguyen TL Grizzle WE Zhang K Hameed O Siegal GP Wei S Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer Am J Clin Pathol 2013 140 4 468 474 10.1309/AJCPZ1D8CALHDXCJ 24045542
25 Canevari M Wells J Pryor E Metastatic CD138+ lobular breast carcinoma mimicking a plasma cell neoplasm American Journal of Clinical Pathology 2019 152 (Supplement 1) S107
26 Kind S Jaretzke A Buscheck F Moller K Dum D Hoflmayer D Hinsch A et al A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer Mol Carcinog 2019 58 12 2306 2315 10.1002/mc.23119 31545001
27 Went PT Lugli A Meier S Bundi M Mirlacher M Sauter G Dirnhofer S Frequent EpCam protein expression in human carcinomas Hum Pathol 2004 35 1 122 128 10.1016/j.humpath.2003.08.026 14745734
28 Wong-Arteta J Rey M Aragon L Gil-Rodriguez E Bujanda L The utility of flow cytometry in the diagnostic work up of malignant effusions due to nonhematopoietic neoplasms Cytometry B Clin Cytom 2020 98 6 504 515 10.1002/cyto.b.21886 32506689
29 Annunziata J Miller ML Park DC Vlad G Bhagat G Alobeid B Detection of nonhematologic neoplasms by routine flow cytometry analysis Am J Clin Pathol 2020 153 1 99 104 10.1093/ajcp/aqz138 31587038
30 Kentrou NA Tsagarakis NJ Tzanetou K Damala M Papadimitriou KA Skoumi D Stratigaki A et al An improved flow cytometric assay for detection and discrimination between malignant cells and atypical mesothelial cells, in serous cavity effusions Cytometry B Clin Cytom 2011 80 5 324 334 10.1002/cyto.b.20608 21695775
31 Chang A Benda PM Wood BL Kussick SJ Lineage-specific identification of nonhematopoietic neoplasms by flow cytometry Am J Clin Pathol 2003 119 5 643 655 10.1309/FU3F-DKYN-8AU0-891N 12760282
32 Lazo PA Functional implications of tetraspanin proteins in cancer biology Cancer Sci 2007 98 11 1666 1677 10.1111/j.1349-7006.2007.00584.x 17727684
33 Huan J Gao Y Xu J Sheng W Zhu W Zhang S Cao J et al Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma Int J Clin Exp Pathol 2015 8 3 3054 3061 26045817
34 Kwon HJ Choi JE Kang SH Son Y Bae YK Prognostic significance of CD9 expression differs between tumour cells and stromal immune cells, and depends on the molecular subtype of the invasive breast carcinoma Histopathology 2017 70 7 1155 1165 10.1111/his.13184 28178752
35 Baek J Jang N Choi JE Kim JR Bae YK CD9 expression in tumor cells is associated with poor prognosis in patients with invasive lobular carcinoma J Breast Cancer 2019 22 1 77 85 10.4048/jbc.2019.22.e9 30941235
36 Kischel P Bellahcene A Deux B Lamour V Dobson R E DEP Clezardin P et al Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases Anticancer Res 2012 32 12 5211 5220 23225418
